Discussions on the reimbursement of ‘Zolgensma’ are finally making progress.

According to industry sources, reimbursement of Novartis Korea’s Spinal Muscular Atrophy (SMA) treatment Zolgensma (onasemnogene abeparvovec-xioi) will be deliberated by the Drug Reimbursement Evaluation Committee of the National Health Insurance Service in coming May.

This progress was made in one year since the company submitted its application for the reimbursement of Zolgensma (onasemnogene abeparvovec-xioi) through the approval-benefit appraisal linkage system. As such, what result this high-priced one-shot treatment will bring remains to be seen.

As Zolgensma is an orphan drug, the drug must